<DOC>
	<DOCNO>NCT02854488</DOCNO>
	<brief_summary>The study global safety surveillance study pregnancy outcome woman expose ipilimumab pregnancy pediatric outcomes 5 year age</brief_summary>
	<brief_title>Yervoy Pregnancy Surveillance Study</brief_title>
	<detailed_description />
	<criteria>Documented exposure Yervoy pregnant within 90 day discontinue treatment Women whose ipilimumab exposure outside window pregnancy exposure Pregnancies paternal exposure Yervoy Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>